THE PROBLEM OF INFORMATIVE PACKAGE LEAFLE TS FOR HORMONAL SUBSTITUTE PREPARATIONS

The package leaflets of hormone preparations used for Hormone Replacem ent Therapy (HRT) in hypoestrogenaemic women contain contraindications , which are taken from the package insert of oral contraceptives: Clot s in the blood vessels (thrombotic disorders), high blood fats, severe diabetes, abnormal red blood cells, deterioration of inherited deafne ss and jaundice not explained by infections, disturbances of the Liver function and of existing or treated hormone-dependent tumours of the breast or of the lining of the womb. Numerous epidemiologic, animal-ex perimental and also clinical studies proved that the cardiovascular ri sk, hepatic discomfort and the influence on the blood system of oestra diol 17-beta have to be evaluated completely differently compared to t he ethinyloestradiol used in oral contraceptives; therefore, many of t he listed contraindications must be reconsidered. In our review we try to emphasise this postulation by scrutinising recent publications.